Broderick Patricia A, Hope Omotola, Okonji Catherine, Rahni David N, Zhou Yueping
Department of Physiology and Pharmacology, City University of New York Medical School, Room Harris 309, Convent Avenue, West 138th Street, New York, NY 10031, USA.
Prog Neuropsychopharmacol Biol Psychiatry. 2004 Jan;28(1):157-71. doi: 10.1016/j.pnpbp.2003.09.032.
There is an increasing awareness that a psychosis, similar to that of schizophrenic psychosis, can be derived from cocaine addiction. Thus, the prototypical atypical antipsychotic medication, clozapine, a 5-HT(2)/DA(2) antagonist, was studied for its effects on cocaine-induced dopamine (DA) and serotonin (5-HT) release in nucleus accumbens (NAcc) of behaving male Sprague-Dawley laboratory rats with In Vivo Microvoltammetry, while animals' locomotor (forward ambulations), an A(10) behavior, was monitored at the same time with infrared photobeams. Release mechanisms for monoamines were determined by using a depolarization blocker, gamma-butyrolactone (gammaBL). BRODERICK PROBE microelectrodes selectively detected release of DA and 5-HT within seconds and sequentially in A(10) nerve terminals, NAcc. Acute and subacute studies were performed for each treatment group. Acute studies are defined as single injection of drug(s) after a stable baseline of each monoamine and locomotor behavior has been achieved. Subacute studies are defined as 24-h follow-up studies on each monoamine and locomotor behavior, in the same animal at which time, no further drug was administered. Results showed that (1) acute administration of cocaine (10 mg/kg ip) (n=5) significantly increased both DA and 5-HT release above baseline (P<.001) while locomotion was also significantly increased above baseline (P<.001). In subacute studies, DA release decreased significantly below baseline (P<.001) and significant decreases in 5-HT release occurred at the 15-min mark and at each time point during the second part of the hour (P<.05); the maximum decrease in 5-HT was 40% below baseline. Locomotor behavior, on the other hand, increased significantly above baseline (P<.05). (2) Acute administration of clozapine/cocaine (20 and 10 mg/kg ip, respectively; n=6) produced a significant block of the cocaine-induced increase in DA (P<.001) and 5-HT release (P<.001). Cocaine-induced locomotion was blocked simultaneously with each monoamine by clozapine as well (P<.001). In subacute studies, DA release continued to be blocked presumably via clozapine by exhibiting a statistically significant decrease (P<.001), but 5-HT release increased significantly (P<.001), while cocaine-induced locomotor activity also continued to be antagonized by clozapine, i.e., locomotor activity exhibited no difference from baseline (P>.05). In summary, acute studies (a) support previous data from this laboratory and others that cocaine acts as a stimulant on the monoamines, DA and 5-HT and on locomotor behavior as well and (b) show that clozapine, 5-HT(2)/DA(2) antagonist, blocked enhanced DA, 5-HT and psychomotor stimulant behavior induced by cocaine. Subacute studies (a) suggest that withdrawal responses occurred in the cocaine group, based on recorded deficiencies in monoamine neurotransmitters (b) show that withdrawal effects in the cocaine group likely presynaptic, were distinguished from locomotor behavior, classically known to be mediated postsynaptically, and finally, (c) suggest that clozapine, with longer lived pharmacokinetic properties, reversed 5-HT cocaine-related withdrawal effects, but was unable to reverse DA cocaine-related withdrawal responses. Taken together with data from this laboratory, in which the 5-HT(2A/2C) antagonist, ketanserin, affected cocaine neurochemistry in much the same way as did clozapine, a mediation by either separate or combined 5-HT(2A/2C) receptors for these clozapine/cocaine interactions, is suggested. Further studies, designed to tease out the responses of selective 5-HT(2A) and 5-HT(2C) receptor compounds to cocaine and clozapine/cocaine, are underway.
人们越来越意识到,一种类似于精神分裂症性精神病的精神病可能源于可卡因成瘾。因此,使用体内微伏安法,研究了典型的非典型抗精神病药物氯氮平(一种5-HT(2)/DA(2)拮抗剂)对行为活跃的雄性斯普拉格-道利实验室大鼠伏隔核(NAcc)中可卡因诱导的多巴胺(DA)和5-羟色胺(5-HT)释放的影响,同时使用红外光束监测动物的运动(向前移动),这是一种A(10)行为。通过使用去极化阻滞剂γ-丁内酯(γBL)来确定单胺的释放机制。BRODERICK PROBE微电极能在数秒内选择性检测出DA和5-HT在A(10)神经末梢、NAcc中的释放,并按顺序进行检测。对每个治疗组进行了急性和亚急性研究。急性研究定义为在每种单胺和运动行为达到稳定基线后单次注射药物。亚急性研究定义为对同一只动物的每种单胺和运动行为进行24小时的随访研究,此时不再给药。结果表明:(1)急性给予可卡因(10mg/kg腹腔注射)(n = 5)显著增加了DA和5-HT的释放,使其高于基线水平(P <.001),同时运动也显著高于基线水平(P <.001)。在亚急性研究中,DA释放显著低于基线水平(P <.001),5-HT释放在15分钟时以及该小时后半段的每个时间点都出现了显著下降(P <.05);5-HT的最大下降幅度比基线低40%。另一方面,运动行为显著高于基线水平(P <.05)。(2)急性给予氯氮平/可卡因(分别为20mg/kg和10mg/kg腹腔注射;n = 6)显著阻断了可卡因诱导的DA(P <.00)和5-HT释放增加(P <.001)。氯氮平同时也阻断了可卡因诱导的单胺与运动(P <.001)。在亚急性研究中,DA释放可能通过氯氮平持续受到阻断,表现出统计学上的显著下降(P <.001),但5-HT释放显著增加(P <.001),而可卡因诱导的运动活动也继续受到氯氮平的拮抗,即运动活动与基线无差异(P >.05)。总之,急性研究(a)支持了本实验室和其他实验室之前的数据,即可卡因对单胺、DA和5-HT以及运动行为都有刺激作用,(b)表明5-HT(2)/DA(2)拮抗剂氯氮平阻断了可卡因诱导的DA、5-HT增强以及精神运动性兴奋行为。亚急性研究(a)表明,基于记录的单胺神经递质缺乏情况,可卡因组出现了戒断反应,(b)表明可卡因组的戒断效应可能是突触前的,与经典已知的由突触后介导的运动行为不同,最后,(c)表明具有较长药代动力学特性的氯氮平逆转了与5-HT相关的可卡因戒断效应,但无法逆转与DA相关的可卡因戒断反应。结合本实验室的数据,其中5-HT(2A/2C)拮抗剂酮色林对可卡因神经化学的影响与氯氮平大致相同,提示这些氯氮平/可卡因相互作用可能是由单独或联合的5-HT(2A/2C)受体介导的。旨在梳理选择性5-HT(2A)和5-HT(2C)受体化合物对可卡因以及氯氮平/可卡因反应的进一步研究正在进行中。